TRL 1068
Alternative Names: TRL-1068Latest Information Update: 24 Oct 2024
At a glance
- Originator Trellis Bioscience
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Bacterial biofilm inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Methicillin-resistant Staphylococcus aureus infections
- Preclinical Bacterial infections
Most Recent Events
- 23 Oct 2024 TRL 1068 receives Fast Track designation for Bacterial endocarditis [IV,Infusion] in USA, before October 2024
- 23 Oct 2024 TRL 1068 receives Fast Track designation for Methicillin-resistant Staphylococcus aureus infections [IV,Infusion] in USA, before October 2024
- 23 Oct 2024 TRL 1068 receives Orphan Drug status for Bacterial endocarditis in USA, before October 2024